Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy.
Several previous reports suggest that thrombospondin (TSP-1) may be a mediator of the antiangiogenic effects of low-dose metronomic cyclophosphamide-based chemotherapy (MC). We conducted a randomized phase II trial evaluating megestrol acetate (n = 44) versus MC (n = 44) in patients having exhausted all standard treatments. We measured the TSP-1 levels at baseline and D15. We did not observe significant differences in TSP-1 at baseline in the two arms (p = 0.07). TSP-1 levels decreased in patients receiving metronomic cyclophosphamide (from 16.6 ± 7.2 µg/ml to 12.8 ± 7.4 µg/ml; p = 0.057). The TSP-1 level was stable in patients receiving megestrol acetate. Nevertheless, the TSP-1 level driven by MC did not correlate to clinical benefit.
Lansiaux
Amélie
A
Centre Oscar Lambret, 3, rue F Combemale, 59020 Lille, France.
Salingue
Sophie
S
Dewitte
Amélie
A
Clisant
Stéphanie
S
Penel
Nicolas
N
D059250:Administration, Metronomic; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000032:analysis*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005602:France; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D019700:Thrombospondin 1 / Q000097:blood*; D013997:Time Factors; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D014408:Biomarkers, Tumor; D019700:Thrombospondin 1; D003520:Cyclophosphamide
Cancer Chemother Pharmacol. 2006 Sep;58(3):354-60
16333676
Ann Oncol. 2002 Jan;13(1):12-5
11863092
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12917-22
14561896
Br J Cancer. 2010 Apr 13;102(8):1207-12
20354522
Clin Cancer Res. 2006 Sep 1;12(17):5190-8
16951238